Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method
Cannabinoids-based pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Thursday that it has entered into a licensing agreement with Remidose Aerosols Inc. to acquire the exclusive rights for advanced cannabis products. Under the deal, current Remidose customers will be serviced through MediPharm starting August 2024, including Canadian direct-to-patient medical platforms and international medical distributors. MediPharm intends to utilize its existing GMP infrastructure, customer channels and wellness sales expertise to expand the customer base of these advanced products in Canada and internationally.
